Thus, the present findings not only revealed TAK1 as a potential molecular target regulating both inflammation and fibrosis in experimental pneumoconiosis, but also identified resveratrol as a TAK1 small-molecule inhibitor, which could be further developed as a promising agent for pneumoconiosis. This evidence concerns the gene MAP3K7 and pneumoconiosis.